PVLAPalvella Therapeutics, Inc.Signing up patients
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Angiokeratomas
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 15 (planned)
- Started
- Apr 2026
- Main results expected
- Aug 2027
- Fully finished
- Sep 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Treatment-Emergent Adverse Events
Measured over: 3 months
Overall Angiokeratoma Investigator Global Assessment (AK-IGA)
Measured over: 3 months
Overall Patient Global Impression of Change (PGI-C)
Measured over: 3 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07552077 · record last updated 2026-04-27 · checked 2026-11-09 15:47 UTC